Singapore: Certara, a drug development and drug safety consultancy firm has launched its D360 software in Japan for providing integrated solution for the query, analysis and visualization of drug discovery and development data.

D360 is used by scientists in both discovery and pre-clinical research. It allows them to search, analyze and share their data without the need for constant IT support, helping to shorten the drug discovery cycle.

In preclinical drug discovery, searching historical control data to answer questions from regulatory agencies often requires the manual review of multiple study reports, which can entail days or weeks of effort. With D360, scientists can obtain the necessary cross-study data views in minutes, allowing them to provide an immediate response to regulatory bodies, and avoiding costly delays in approval processes and disruptions to ongoing work.

"We are proud to introduce D360 to the Japanese market," said Dr Edmundo Muniz, CEO, Certara. "D360 is a well-established, trusted drug discovery and development data access and analysis solution that can help pharma and biotech companies to improve the time to and accuracy of their go/no-go product decisions by providing scientists with on-demand access to their desired data in their preferred format."

D360 has been deployed in life sciences research organizations including Pfizer, Boehringer Ingelheim, Medivir AB, Plexxikon, and Agios.